These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9605807)

  • 1. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.
    Osin P; Crook T; Powles T; Peto J; Gusterson B
    Lancet; 1998 May; 351(9114):1487. PubMed ID: 9605807
    [No Abstract]   [Full Text] [Related]  

  • 2. [Is low-dose tamoxifen an effective therapy for breast carcinoma in situ?].
    Ivanova OA; Zhil'tsova EK; Barash NIu; Ivanov VG; Ermachenkova AM
    Vopr Onkol; 2011; 57(5):601-3. PubMed ID: 22238929
    [No Abstract]   [Full Text] [Related]  

  • 3. Ductal carcinoma in situ.
    Venniyoor A
    Aust Fam Physician; 2006 May; 35(5):278-9; author reply 279. PubMed ID: 16708448
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA-associated breast cancer: absence of a characteristic immunophenotype.
    Robson M; Rajan P; Rosen PP; Gilewski T; Hirschaut Y; Pressman P; Haas B; Norton L; Offit K
    Cancer Res; 1998 May; 58(9):1839-42. PubMed ID: 9581822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians.
    Peshkin BN; Isaacs C; Finch C; Kent S; Schwartz MD
    J Clin Oncol; 2003 Dec; 21(23):4322-8. PubMed ID: 14645421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammography of breast carcinoma in women who have mutations of the breast cancer gene BRCA1: initial experience.
    Helvie MA; Roubidoux MA; Weber BL; Merajver SD
    AJR Am J Roentgenol; 1997 Jun; 168(6):1599-602. PubMed ID: 9168735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.
    Cunnick GH; Mokbel K
    Lancet; 2003 Oct; 362(9390):1154; author reply 1155-6. PubMed ID: 14550707
    [No Abstract]   [Full Text] [Related]  

  • 9. Is it rational to extend the duration of preventive endocrine treatment in hormone receptor positive ductal carcinoma in situ?
    Altundag K
    J BUON; 2018; 23(3):835. PubMed ID: 30003760
    [No Abstract]   [Full Text] [Related]  

  • 10. Microinvasive lobular carcinoma of the breast.
    Howat AJ; Armour A; Ellis IO
    Histopathology; 2000 Nov; 37(5):477-8. PubMed ID: 11119139
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers.
    van der Groep P; van Diest PJ; Menko FH; Bart J; de Vries EG; van der Wall E
    J Clin Pathol; 2009 Oct; 62(10):926-30. PubMed ID: 19541683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormonal and genotoxic aspects of BRCA1-associated carcinogenesis].
    Bershteĭn LM
    Vopr Onkol; 2007; 53(6):642-53. PubMed ID: 18416131
    [No Abstract]   [Full Text] [Related]  

  • 13. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ.
    Zammit C; Yelland A; Deutsch G
    Lancet; 2003 Oct; 362(9390):1154; author reply 1155-6. PubMed ID: 14550708
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular markers and therapeutic targets in ductal carcinoma in situ.
    Boland GP; Knox WF; Bundred NJ
    Microsc Res Tech; 2002 Oct; 59(1):3-11. PubMed ID: 12242692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance with tamoxifen in women with breast cancer and a BRCA1 or BRCA2 mutation.
    Narod SA
    J Clin Oncol; 2010 Nov; 28(33):e698-9; author reply e700. PubMed ID: 20921464
    [No Abstract]   [Full Text] [Related]  

  • 16. Designer estrogens: breast cancer benefit, remaining questions.
    Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
    [No Abstract]   [Full Text] [Related]  

  • 17. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
    Calzada L; Salazar EL; Pedron Nuevo N
    Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
    Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Tamoxifen may be an effective treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
    Cappelletti V; Veneroni S; Coradini D; Oriana S; Tomasic G; Younes M; Daidone MG
    J Natl Cancer Inst; 2003 Apr; 95(8):629-30. PubMed ID: 12697859
    [No Abstract]   [Full Text] [Related]  

  • 20. HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy.
    Collins LC; Schnitt SJ
    Mod Pathol; 2005 May; 18(5):615-20. PubMed ID: 15696127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.